PPA
KNTE

Parametric Portfolio Associates’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Parametric Portfolio Associates’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$410K Buy
36,423
+22,743
+166% +$250K ﹤0.01% 3178
2021
Q4 		$242K Sell
13,680
-13,243
-49% -$279K ﹤0.01% 3356
2021
Q3 		$620K Buy
+26,923
New +$586K ﹤0.01% 3008

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parametric Portfolio Associates's KNTE Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Kinnate Biopharma Inc. Common Stock (KNTE) stake by 166% in Q1 2022, buying an estimated $250K and bringing the position to 36,423 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Parametric Portfolio Associates first reported a position in KNTE in Q3 2021 and has held it in 3 quarters since. The position peaked at $620K in Q3 2021. 76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • Parametric Portfolio Associates held 36,423 shares of Kinnate Biopharma Inc. Common Stock worth $410K as of Q1 2022.
  • Parametric Portfolio Associates bought 22,743 Kinnate Biopharma Inc. Common Stock shares in Q1 2022, an estimated $250K.
  • Kinnate Biopharma Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3178 holding.
  • Parametric Portfolio Associates first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and has held it in 3 quarters since.
  • Parametric Portfolio Associates's Kinnate Biopharma Inc. Common Stock position peaked at $620K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.